molecules of the month

compound 29

FGFR2/3 inhibitor

favorable PK profile in rats

opt. from HTS + SBDD & scaffold hopping

J. Med. Chem., 10 November 2022

Incyte Corporation, Wilmington, DE

compound 29 chemical structure FGFR2/3 inhibitor- Incyte Corporation, Wilmington, DE
3 mins read

Overcoming FGFR mutation resistance and FGFR1-mediated hyperphosphatemia toxicity through isoform-selective FGFR2/3 inhibition. “Compound 29” is an ATP-competitive fibroblast growth factor receptor (FGFR) 2/3 inhibitor with subnanomolar potency. FGFR is a receptor tyrosine kinase (RTK) involved in cell differentiation, proliferation, migration and survival. Aberrations in the FGFR1-4 gene are related to oncogenesis and found in 5-10% of all human cancers, with a higher incidence of 10-30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. FGFR1-3 inhibitors erdafitinib (Balversa), pemigatinib (Pemazyre), and infigratinib (Truseltiq) were FDA-approved in 2019-21, but clinical resistance has been reported due to gatekeeper (GK) mutations FGFR2V564I/L/M/F or FGFR3V555I/L/M/F such that the 3,5-dimethoxyphenyl group can no longer reside in the hydrophobic pocket of the ATP-binding site. Even further, it has been…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: